Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial

Abstract

Background and objective: The dual orexin receptor antagonist daridorexant, studied in two phase III trials, dose-dependently improved objective and subjective sleep variables and daytime functioning in adults with insomnia. Because treatment of insomnia in older adults is challenging and has limited options, the purpose of the current analysis was to further analyse the phase III trial studying the higher doses of daridorexant, those that showed efficacy (daridorexant 50 mg, daridorexant 25 mg and placebo, nightly for 3 months), and compare the safety and efficacy of daridorexant in patients aged ≥ 65 ('older adults') to those aged < 65 years ('younger adults').

Methods: Analyses by age (≥ 65 years, n = 364; < 65 years, n = 566) were performed on data from the randomised, double-blind, placebo-controlled Trial 1 in adult patients with insomnia (NCT03545191). Efficacy endpoints included a change from baseline at month 1 and month 3 in polysomnography-measured wake after sleep onset (WASO) and latency to persistent sleep (LPS), self-reported total sleep time (sTST) and daytime functioning assessed using the validated Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). Safety endpoints included adverse events and the Visual Analog Scale for morning sleepiness.

Results: At baseline, mean [standard deviation] WASO was numerically greater (110 [39] vs 92 [38] min) in older than younger adults, while LPS was comparable (~ 65 min). Mean baseline IDSIQ total and all domain scores were numerically lower (i.e. better) in older adults. Daridorexant caused similar reductions in WASO and LPS, and similar increases in sTST, from baseline, in both age groups; improvements were numerically greater with daridorexant 50 mg than 25 mg. At month 3, daridorexant 50 mg, compared with placebo, decreased WASO by a least-squares mean of 19.6 (95% confidence interval 9.7, 29.5) in older patients versus 17.4 min (10.7, 24.0) in younger patients and decreased LPS by a least-squares mean of 14.9 (7.5, 22.3) in older patients versus 9.7 min (3.7, 15.7) in younger patients. Daridorexant 50 mg increased sTST from baseline to month 3 by a least-squares mean of 59.9 (49.6, 70.3) in older patients versus 57.1 min (48.9, 65.3) in younger patients. Daridorexant 50 mg progressively improved IDSIQ total and domain scores from week 1 onwards similarly in both groups; daridorexant 25 mg improved IDSIQ scores, but only in younger adults. In both age groups, in comparison with placebo, the overall incidence of adverse events was comparable, and there were fewer falls on daridorexant. Daridorexant improved Visual Analog Scale morning sleepiness in both groups; daridorexant 50 mg increased the mean (standard deviation) Visual Analog Scale morning sleepiness score by 15.9 (20.7) in older adults and by 14.9 (18.7) in younger adults from baseline to month 3. In older adults, there was one case of sleep paralysis, and no cases of narcolepsy, cataplexy, or complex sleep behaviour.

Conclusions: In older patients with insomnia, as in younger patients, the efficacy of daridorexant is maximal on night-time and daytime variables at the higher dose of 50 mg. Older patients particularly require this dose to improve daytime functioning. Older patients are not at an increased risk of adverse events or residual effects the next morning after night-time administration of daridorexant, even at 50 mg. The dose of daridorexant does not need to be decreased for older patients.

Clinical trial registration: ClinicalTrials.gov (NCT03545191) [first posted: 4 June, 4 2018], https://ichgcp.net/clinical-trials-registry/NCT03545191 .

Conflict of interest statement

IF reports consulting fees from Bayer, Bioproject, Hennig, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, and STADA and speaker activity/reimbursement from Hennig, Idorsia Pharmaceuticals and Medice. CLAB reports consultancy fees from Bioproject, Takeda and Jazz Pharmaceuticals during the conduct of the trials. DM has been a clinical investigator for Apnimed, Eisai, Idorsia Pharmaceuticals, Imbrium, Janssen, Jazz Pharmaceuticals, Merck, Sage, Takeda and Vanda. WVM reports scientific advisor fees from Idorsia Pharmaceuticals and Janssen, and royalties from Wolter Kluwer. DSK and SP are employees of Idorsia Pharmaceuticals. IDSIQ was developed by Buysse DJ, Thompson W, Scott J, Franzen PL, Germain A Hall M, Moul DE, Nofzinger EA and Kupfer DJ of the University of Pittsburgh and as amended by Idorsia Pharmaceuticals Ltd. IDSIQ© 2020, University of Pittsburg. All rights reserved. IDSIQ-14 derivative created 2020 by Idorsia Pharmaceuticals Ltd under license and distributed by Idorsia Pharmaceuticals Ltd under license.

© 2022. The Author(s).

Figures

Fig. 1

Effect of daridorexant on objective and subjective sleep parameters by age group. Mean change from baseline in a wake after sleep onset (WASO), b latency to persistent sleep (LPS) and c self-reported total sleep time (sTST) in younger adults aged < 65 years and older adults aged ≥ 65 years administered daridorexant 25 mg, daridorexant 50 mg and placebo. The WASO and LPS values are the mean of polysomnography recordings obtained over 2 consecutive nights during the 3-month double-blind treatment period. Data for sTST are based on the mean of daily entries in the 7 days before polysomnography nights. Error bars show standard errors. SEM standard error of the mean

Fig. 2

Effect of daridorexant on Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) total scores and domain scores by age group. Weekly mean change from baseline in a IDSIQ total score, b IDSIQ sleepiness domain score, c IDSIQ mood domain score and d IDSIQ alert/cognition domain score in younger adults aged < 65 years and older adults aged ≥ 65 years administered daridorexant 25 mg, daridorexant 50 mg and placebo. Lower IDSIQ scores indicate better patient-perceived daytime functioning

Fig. 3

Effect of daridorexant on Visual Analog Scale (VAS) depth and quality of sleep, daytime alertness and ability to function over time by age group. Weekly mean change from baseline in VAS a depth of sleep, b quality of sleep, c daytime alertness and d ability to function in younger adults aged < 65 years and older adults aged ≥ 65 years administered daridorexant 25 mg, daridorexant 50 mg and placebo. Higher VAS scores indicate better scores

Fig 4

Effect of daridorexant on the Visual Analog Scale (VAS) morning sleepiness score over time by age group. Safety analysis set. Mean weekly change from baseline in VAS morning sleepiness score (mm) in younger adults aged